Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Increase in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 25,740 shares, a growth of 97.4% from the December 31st total of 13,039 shares. Based on an average daily trading volume, of 31,347 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.7% of the shares of the stock are short sold. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 31,347 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,984 shares of the company’s stock, valued at approximately $33,000. Two Sigma Investments LP owned approximately 0.33% of Kiora Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Kiora Pharmaceuticals Price Performance

Shares of NASDAQ KPRX traded up $0.10 on Friday, hitting $2.40. The company’s stock had a trading volume of 142,850 shares, compared to its average volume of 61,403. The stock has a 50 day moving average of $2.08 and a 200-day moving average of $2.43. The company has a market capitalization of $8.83 million, a price-to-earnings ratio of -1.15 and a beta of -0.89. Kiora Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $4.18.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings data on Friday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.73. Sell-side analysts expect that Kiora Pharmaceuticals will post 1.28 EPS for the current fiscal year.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.